Joanne Wuensch
Stock Analyst at Citigroup
(4.29)
# 388
Out of 5,147 analysts
451
Total ratings
63.18%
Success rate
11.11%
Average return
Main Sectors:
Stocks Rated by Joanne Wuensch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Maintains: Neutral | $75 → $92 | $86.68 | +6.14% | 10 | Feb 20, 2026 | |
| BLCO Bausch + Lomb | Maintains: Buy | $20 → $21 | $18.30 | +14.75% | 7 | Feb 19, 2026 | |
| PODD Insulet | Maintains: Buy | $380 → $345 | $246.61 | +39.90% | 17 | Feb 19, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $94 → $98 | $98.44 | -0.45% | 24 | Feb 11, 2026 | |
| HAE Haemonetics | Maintains: Neutral | $88 → $75 | $63.32 | +18.45% | 11 | Feb 6, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $130 → $102 | $76.85 | +32.73% | 36 | Feb 5, 2026 | |
| ISRG Intuitive Surgical | Maintains: Neutral | $635 → $590 | $503.51 | +17.18% | 19 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Buy | $155 → $140 | $116.35 | +20.33% | 23 | Jan 23, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $232 → $250 | $248.43 | +0.63% | 17 | Jan 22, 2026 | |
| PEN Penumbra | Downgrades: Neutral | $350 → $374 | $344.39 | +8.60% | 27 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $455 → $420 | $387.46 | +8.40% | 15 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $9.1 | $5.16 | +76.36% | 14 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $113 → $125 | $120.40 | +3.82% | 23 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $88 | $84.27 | +4.43% | 8 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $75 | $78.70 | -4.70% | 8 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $96 → $101 | $86.47 | +16.80% | 22 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $22 | $25.30 | -13.04% | 21 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $77 | $73.43 | +4.86% | 17 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $88 | $83.67 | +5.18% | 22 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $11 | $11.38 | -3.34% | 16 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $21 | $20.37 | +3.09% | 22 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $205 → $242 | $133.75 | +80.93% | 22 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $112 | $97.66 | +14.68% | 22 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $4.15 | $1.58 | +162.66% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $220 → $250 | $176.48 | +41.66% | 5 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $67 → $69 | $87.18 | -20.85% | 5 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $109 → $127 | $256.26 | -50.44% | 6 | Dec 10, 2018 |
Integer Holdings
Feb 20, 2026
Maintains: Neutral
Price Target: $75 → $92
Current: $86.68
Upside: +6.14%
Bausch + Lomb
Feb 19, 2026
Maintains: Buy
Price Target: $20 → $21
Current: $18.30
Upside: +14.75%
Insulet
Feb 19, 2026
Maintains: Buy
Price Target: $380 → $345
Current: $246.61
Upside: +39.90%
Zimmer Biomet Holdings
Feb 11, 2026
Maintains: Neutral
Price Target: $94 → $98
Current: $98.44
Upside: -0.45%
Haemonetics
Feb 6, 2026
Maintains: Neutral
Price Target: $88 → $75
Current: $63.32
Upside: +18.45%
Boston Scientific
Feb 5, 2026
Maintains: Buy
Price Target: $130 → $102
Current: $76.85
Upside: +32.73%
Intuitive Surgical
Jan 23, 2026
Maintains: Neutral
Price Target: $635 → $590
Current: $503.51
Upside: +17.18%
Abbott Laboratories
Jan 23, 2026
Maintains: Buy
Price Target: $155 → $140
Current: $116.35
Upside: +20.33%
Johnson & Johnson
Jan 22, 2026
Maintains: Buy
Price Target: $232 → $250
Current: $248.43
Upside: +0.63%
Penumbra
Jan 16, 2026
Downgrades: Neutral
Price Target: $350 → $374
Current: $344.39
Upside: +8.60%
Dec 11, 2025
Maintains: Buy
Price Target: $455 → $420
Current: $387.46
Upside: +8.40%
Dec 11, 2025
Maintains: Neutral
Price Target: $5.5 → $9.1
Current: $5.16
Upside: +76.36%
Dec 11, 2025
Maintains: Buy
Price Target: $113 → $125
Current: $120.40
Upside: +3.82%
Dec 11, 2025
Maintains: Neutral
Price Target: $83 → $88
Current: $84.27
Upside: +4.43%
Dec 11, 2025
Maintains: Neutral
Price Target: $62 → $75
Current: $78.70
Upside: -4.70%
Dec 11, 2025
Maintains: Buy
Price Target: $96 → $101
Current: $86.47
Upside: +16.80%
Dec 11, 2025
Maintains: Neutral
Price Target: $16 → $22
Current: $25.30
Upside: -13.04%
Dec 11, 2025
Maintains: Buy
Price Target: $75 → $77
Current: $73.43
Upside: +4.86%
Dec 8, 2025
Maintains: Neutral
Price Target: $72 → $88
Current: $83.67
Upside: +5.18%
Oct 31, 2025
Maintains: Sell
Price Target: $12 → $11
Current: $11.38
Upside: -3.34%
Oct 31, 2025
Maintains: Neutral
Price Target: $26 → $21
Current: $20.37
Upside: +3.09%
Oct 31, 2025
Maintains: Buy
Price Target: $205 → $242
Current: $133.75
Upside: +80.93%
Oct 7, 2025
Maintains: Buy
Price Target: $101 → $112
Current: $97.66
Upside: +14.68%
May 22, 2025
Maintains: Neutral
Price Target: $6.5 → $4.15
Current: $1.58
Upside: +162.66%
Dec 12, 2022
Upgrades: Neutral
Price Target: $220 → $250
Current: $176.48
Upside: +41.66%
Nov 17, 2022
Maintains: Neutral
Price Target: $67 → $69
Current: $87.18
Upside: -20.85%
Dec 10, 2018
Upgrades: Outperform
Price Target: $109 → $127
Current: $256.26
Upside: -50.44%